ACTH Medication-Driven Changes: What Every Lab Result Means

What ACTH measures, and why the reference range is not the whole story

ACTH (adrenocorticotropic hormone, corticotropin) is secreted by the anterior pituitary and stimulates cortisol production by the adrenal cortex. It is distinct from CRH (the hypothalamic hormone that stimulates ACTH release) and from cosyntropin (Cortrosyn), the synthetic ACTH analog used to test adrenal reserve. A plasma ACTH level only makes sense alongside a simultaneous cortisol, the time of day it was drawn, and a current medication list.

Laboratories typically report a morning (08:00) reference interval in the general range of 10 to 60 pg/mL, though immunoassay platforms differ enough that a value flagged as high on one lab's report might sit inside another lab's normal range. Afternoon values are physiologically lower because ACTH secretion follows a diurnal rhythm. Some endocrinology practices work with a narrower "optimal" target inside the standard reference range when trying to confirm a well-regulated axis, but this is a clinical practice pattern rather than a formally validated cutoff, and it should not be used to diagnose disease on its own.

ACTH is also unstable outside the body. Samples that sit at room temperature before processing can lose a meaningful fraction of immunoreactive hormone, which is why proper collection (chilled EDTA tube, prompt centrifugation, rapid freezing) matters as much as the biology itself. A result drawn or handled incorrectly should be treated as unreliable and repeated rather than interpreted.

The single sentence worth remembering: an unexpected ACTH result should first be checked against the patient's medication list and the timing and handling of the draw, because glucocorticoids, adrenal enzyme inhibitors, and mifepristone each produce a distinct and predictable direction of change, and only a pattern that remains unexplained after that check warrants a formal adrenal or pituitary workup.

How glucocorticoids suppress ACTH

Exogenous glucocorticoids (prednisone, dexamethasone, hydrocortisone, and others) suppress ACTH by reducing hypothalamic CRH output and by directly inhibiting ACTH release from the pituitary. This is the most common medication-driven cause of a low ACTH result in clinical practice.

The degree of suppression tracks with dose, potency, and duration:

• Short courses of low-dose dexamethasone (as used in the low-dose dexamethasone suppression test) reliably suppress morning ACTH within hours, which is the pharmacologic basis of that test.
• Chronic oral corticosteroid use, particularly at higher doses sustained for several weeks or longer, is well established as a cause of HPA-axis suppression, though the exact proportion of patients affected varies across published studies and depends on dose, duration, and individual variability. A precise percentage should not be quoted without checking the specific study population it came from.
• Inhaled and topical corticosteroids can also suppress the axis at high cumulative doses, an effect that is better documented through cortisol suppression as a proxy than through ACTH measurements directly.

Recovery after stopping long-term glucocorticoids is often slow and uneven. Pituitary ACTH output typically recovers before adrenal cortisol responsiveness does, and some patients take many months to normalize on a cosyntropin stimulation test. A single normal ACTH value after stopping steroids does not confirm that the adrenal glands have recovered; a stimulation test is the more reliable check when that question matters clinically. Reported recovery timelines vary across studies and should be treated as a general pattern rather than a fixed schedule for any individual patient.

Drugs that raise ACTH by blocking cortisol synthesis

Several drugs lower cortisol by blocking adrenal steroidogenic enzymes. When cortisol falls, the pituitary loses its negative feedback signal and ACTH rises, sometimes sharply. This rise is the intended diagnostic signal in some tests and an expected side effect during treatment with these drugs for Cushing's syndrome.

Metyrapone blocks 11-beta-hydroxylase (CYP11B1), the final step in cortisol synthesis. In a patient with an intact HPA axis, metyrapone causes cortisol to fall and ACTH to rise within hours, which is why a metyrapone stimulation test is used as a second-line confirmatory test for Cushing's syndrome in current endocrine society guidance. Used therapeutically for Cushing's disease, metyrapone keeps ACTH persistently elevated, and clinicians watch for cortisol "escape" and for adrenal androgen side effects such as acne and hirsutism.

Ketoconazole, at doses used to treat Cushing's syndrome, inhibits several adrenal cytochrome P450 enzymes and reduces cortisol synthesis, which raises ACTH as the feedback loop responds. The magnitude and time course of this rise vary across published case series; a specific percentage increase should be verified against the primary literature rather than treated as fixed.

Osilodrostat (Isturisa), FDA-approved for Cushing's disease, and levoketoconazole (Recorlev), FDA-approved for endogenous Cushing's syndrome, work through the same general mechanism, blocking adrenal cortisol synthesis and producing a compensatory ACTH rise. Anyone reviewing labs for a patient on either drug should expect ACTH to run above that patient's pretreatment baseline as a mechanistic consequence of the drug working as intended, not as a new finding requiring separate workup.

Mifepristone: a lab pattern that looks like disease but is not

Mifepristone (Korlym) is FDA-approved for hyperglycemia associated with endogenous Cushing's syndrome. It blocks the glucocorticoid receptor rather than lowering cortisol production, which creates an unusual and important lab pattern: cortisol rises (the pituitary no longer senses cortisol acting on its own receptor and keeps signaling), and ACTH rises in parallel because the drug does nothing to reduce adrenal output.

Patients on mifepristone will show both high ACTH and high cortisol at the same time. On paper this resembles severe endogenous hypercortisolism, but it is a predictable drug effect, not a new or worsening disease process. Cortisol and urinary free cortisol are not useful monitoring tools in these patients because the receptor blockade makes them uninterpretable. Clinical monitoring instead relies on blood glucose, blood pressure, and physical signs of hypercortisolism or, conversely, of over-blockade (which can cause a clinical picture resembling adrenal insufficiency despite high measured cortisol). The FDA label describes dexamethasone as the treatment approach if drug-induced adrenal insufficiency is suspected in this setting; the exact management should follow current prescribing information rather than this summary.

Other drugs and situations that shift ACTH

Etomidate, an intravenous anesthetic and sedative, transiently inhibits the same adrenal enzyme metyrapone targets (11-beta-hydroxylase). This causes a brief drop in cortisol and a compensatory, short-lived ACTH rise, an effect that has drawn particular attention in critically ill and septic patients where even transient adrenal suppression may matter clinically. The values typically normalize within about a day.

Mitotane (Lysodren), used in adrenocortical carcinoma, destroys adrenal cortical tissue and causes true primary adrenal insufficiency, with ACTH often markedly elevated. Patients on mitotane require glucocorticoid and mineralocorticoid replacement, and a falling ACTH over time can suggest residual adrenal function while a persistently high value is consistent with adequate cytotoxic effect. Precise cutoffs for treatment response should come from the treating oncology or endocrinology team rather than a general reference value.

Pasireotide (Signifor), a somatostatin analog approved for Cushing's disease, acts directly on somatostatin receptor subtype 5 on corticotroph cells to suppress ACTH secretion at the pituitary itself, which is a different mechanism from the enzyme inhibitors above. A 2020 phase III study of the long-acting, once-monthly formulation reported improvements in clinical signs of hypercortisolism and in quality of life among patients with Cushing's disease (Fleseriu et al., 2020). That trial is the appropriate primary source to check before quoting specific response rates or ACTH-normalization figures for pasireotide; readers who need exact numbers for clinical decisions should pull the full paper rather than rely on a secondary summary.

Cabergoline, a dopamine D2 agonist used mainly for hyperprolactinemia, suppresses ACTH in some patients with Cushing's disease because some corticotroph tumors express D2 receptors. Response is inconsistent across patients, and cabergoline is not a first-line Cushing's treatment, but its ACTH-lowering effect should be kept in mind when interpreting labs in a patient taking it for a prolactinoma.

SSRIs and other psychiatric medications have been reported in the general research literature to modestly reduce basal HPA-axis activity with chronic use, with effects on ACTH reported less consistently than effects on cortisol. This is unlikely to push ACTH outside a normal reference range on its own but is worth considering when a value sits near the lower boundary of normal in a patient on long-term SSRI therapy.

Licorice root and other 11-beta-hydroxysteroid dehydrogenase type 2 inhibitors raise effective cortisol activity at the tissue level, which can secondarily suppress ACTH. This is easy to miss because licorice is often taken as a supplement rather than disclosed as a medication.

Distinguishing primary from secondary adrenal insufficiency when drugs are involved

The core clinical use of ACTH testing is separating primary adrenal insufficiency (the adrenal glands cannot respond) from secondary adrenal insufficiency (the pituitary or hypothalamus is not signaling adequately). Medications complicate this distinction in predictable ways.

In primary adrenal insufficiency, the adrenals fail and the pituitary responds with high, sometimes very high, ACTH. Endocrine Society guidance describes a morning ACTH clearly above the upper reference limit, generally more than twice that limit, together with low cortisol, as supportive of primary adrenal insufficiency. Drug-induced causes of this pattern include mitotane and, less commonly, other agents that damage adrenal tissue directly.

In secondary adrenal insufficiency, ACTH and cortisol are both low because the pituitary itself is suppressed. Exogenous glucocorticoid use is by far the most common drug-related cause. A low morning ACTH with a low morning cortisol in a patient with a recent history of meaningful glucocorticoid exposure is consistent with drug-induced secondary adrenal insufficiency, though a cosyntropin (Cortrosyn) stimulation test remains the more definitive confirmatory test when the diagnosis will change management, because a suppressed ACTH does not always mean the adrenal glands have lost the ability to respond.

What is established, what is plausible, and what is not established

• Established: exogenous glucocorticoids suppress ACTH through central HPA-axis feedback; adrenal enzyme inhibitors (metyrapone, ketoconazole, osilodrostat, levoketoconazole) raise ACTH by lowering cortisol synthesis; mifepristone raises both ACTH and cortisol by blocking the glucocorticoid receptor; ACTH degrades quickly in improperly handled samples.
• Plausible but not firmly quantified for general use: the exact percentage of patients who develop clinically significant HPA suppression at a given steroid dose and duration, the precise time course of ACTH rise on ketoconazole or osilodrostat, and the magnitude of SSRI effects on ACTH specifically. These vary across studies and populations and should not be quoted as a single fixed number without checking the source study.
• Not established from the material reviewed here: a validated "optimal" ACTH range distinct from the standard laboratory reference interval; a universal recovery timeline for HPA-axis function after stopping any specific glucocorticoid regimen.

A decision framework for an unexpected ACTH result

Use this sequence before assuming a new adrenal or pituitary diagnosis. It does not replace clinical judgment or a stimulation test when one is indicated.

If a patient has symptoms of adrenal crisis (severe fatigue, vomiting, low blood pressure, confusion) regardless of what the ACTH value shows, this is a medical emergency and requires urgent evaluation, not a wait for confirmatory labs.

Hormone therapy and testosterone replacement: an indirect effect, not a direct one

Testosterone replacement therapy and estrogen-based hormone therapy do not directly suppress ACTH secretion at doses typically used for hormone replacement, but they change how cortisol is measured. Oral estrogens raise cortisol-binding globulin (CBG), which raises total cortisol readings without necessarily changing free cortisol or ACTH, so a patient on oral estrogen can show a "high" total cortisol that is not clinically meaningful. Transdermal estradiol raises CBG less and is generally the preferred route when serial cortisol monitoring matters. Standard-dose testosterone replacement has not been consistently shown to alter basal ACTH in published pharmacokinetic data; when ACTH is abnormal in a patient on TRT, the more likely explanation is a concurrent glucocorticoid or adrenal-modifying drug rather than the testosterone itself.

Specimen handling and interference that mimic a medication effect

Because ACTH is fragile and immunoassay-based, several non-drug factors can look like a medication effect on the report:

• Improper handling. A sample left at room temperature too long, or not centrifuged and frozen quickly, can show a falsely low ACTH that has nothing to do with the patient's medications.
• Biotin supplementation. High-dose biotin can interfere with streptavidin-biotin based immunoassays and produce falsely low ACTH results. The FDA has issued public warnings about biotin interference with various hormone immunoassays; patients on high-dose biotin should stop it for a few days before testing if their clinician advises it, and any unexpected low result in a biotin user should prompt a repeat test rather than immediate treatment decisions.
• Heterophilic antibodies. These affect a small minority of patients and can spuriously raise ACTH on some immunoassay platforms. A result that does not fit the clinical picture is a reasonable trigger for a repeat test on a different assay platform.

When to seek urgent care rather than wait for lab interpretation

Signs of adrenal crisis, severe weakness, persistent vomiting, abdominal pain, confusion, or low blood pressure, in someone who has recently stopped a long-term glucocorticoid, is on an adrenal enzyme inhibitor, or has any other reason to suspect adrenal insufficiency, warrant emergency evaluation. Do not wait for an ACTH or cortisol result to come back before seeking care in that situation.